Skip to content
To the full analysis

Nektar Therapeutics stock: balance sheet and debt

NKTR
$37.25Closing price of 12 Nov 2026MEQIRI Score 29 out of 100

Nektar Therapeutics has a debt to equity ratio of 1.66.

Daily figure as of 13 Nov 2026

Debt / Equity
1.66
Interest coverage
−5.3x
Current ratio
4.97
Cash & equivalents
$245.75M
Total assets
$280.41M
Equity ratio
32%
Goodwill
not reported separately
Net debt
−$96.84M
More cash than debt

Total assets and equity ratio

How large the balance sheet of Nektar Therapeutics is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$768.18M$82.06M$78.43M29.6%−$20.52M
2007$725.1M$81.11M$78.43M29.6%−$143.39M
2008$560.54M$76.5M$76.5M33.9%−$143.69M
2009$575.52M$76.5M$76.5M17.8%−$162.46M
2010$521.23M$76.5M$76.5M17.4%−$83.96M
2011$606.55M$76.5M$76.5M32.6%−$11.63M
2012$497.79M$76.5M$76.5M9.4%−$140.59M
2013$434.53M$76.5M$76.5M−20.7%−$103.98M
2014$441.62M$76.5M$76.5M8.2%−$104.17M
2015$502.06M$76.5M$76.5M1.3%−$61.42M
2016$568.87M$76.5M$76.5M15.5%−$140.51M
2017$508.87M$76.5M$76.5M17.3%−$50.93M
2018$2.15B$76.5M$76.5M79.9%−$1.09B
2019$1.98B$76.5M$76.5M71.1%−$916.73M
2020$1.54B$76.5M$76.5M70.0%−$911.61M
2021$1.12B$76.5M$76.5M60.8%−$590.78M
2022$710.6M$76.5M$76.5M51.6%−$373.48M
2023$398.03Mnot reported separatelynot reported separately32.9%−$185.84M
2024$303.85Mnot reported separatelynot reported separately20.0%−$152.66M
2025$280.41Mnot reported separatelynot reported separately32.0%−$96.84M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$458.64M$227.06M$438.12M1.93
2007$482.35M$214.44M$338.97M1.58
2008$378.99M$190.15M$235.3M1.24
2009$396.21M$102.37M$233.76M2.28
2010$315.93M$90.66M$231.97M2.56
2011$241.17M$197.81M$229.54M1.16
2012$277.19M$47.02M$136.61M2.91
2013$237.03M−$89.9M$133.05M−1.48
2014$237.82M$36.33M$133.65M3.68
2015$308.94M$6.43M$247.53M38.5
2016$389.1M$88.13M$248.6M2.82
2017$296.13M$87.83M$245.21M2.79
2018$1.34B$1.72B$246.95M0.14
2019$1.32B$1.41B$408.14M0.29
2020$1.06B$1.08B$150.29M0.14
2021$733.96M$679.51M$143.18M0.21
2022$504.98M$366.64M$131.5M0.36
2023$303.62M$130.99M$117.78M0.9
2024$255.23M$60.74M$102.56M1.69
2025$245.75M$89.83M$148.91M1.66

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2019)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy